Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Validation of a 2-Gene Blood Test for Kawasaki Disease in Febrile Children.

JAMA network open·2026

Same author

Comparison of depression risk and depression-related ambulatory care utilization in sarcopenia patients with and without Chinese herbal medicine.

World journal of psychiatry·2025

Same author

Identification of novel genetic biomarkers for ChAdOx1 nCoV-19 mediated immunogenicity.

Frontiers in immunology·2025

Same author

Revised NMS-driven pipeline for heart valve regurgitation and Kawasaki disease coronary aneurysm localization.

Computers in biology and medicine·2025

Same author

Cross-ancestry discovery of genetic risk variants for lean metabolic dysfunction-associated steatotic liver disease.

Cell & bioscience·2025

Same author

Nano-Bubble Hydrogen Water in Wet-Wrap Dressing Improves the Severity of Pediatric Patients With Atopic Dermatitis.

Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners·2025

Search research articles

Related Experiment Video

Updated: May 29, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

Genetic polymorphisms in Kawasaki disease.

Ho-chang Kuo¹, Wei-chiao Chang

¹Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan, China.

Acta Pharmacologica Sinica

|September 6, 2011

Summary

Kawasaki disease (KD) genetics is complex, involving gene-environment interactions. Recent studies reveal ITPKC pathway involvement and identify key genetic loci, advancing understanding of KD pathogenesis.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

Immunology
Genetics
Pediatrics

Background:

Kawasaki disease (KD) is an acute febrile systemic vasculitis of unknown etiology.
Genetic and environmental factors are implicated in KD pathogenesis.
Recent advances in genetic studies have shed light on KD's molecular mechanisms.

Purpose of the Study:

To review genetic polymorphisms associated with Kawasaki disease.
To explore the clinical implications of genetic variants in KD.
To elucidate molecular mechanisms underlying genetic regulation in KD pathogenesis.

Main Methods:

Review of genetic association studies.
Analysis of genome-wide association studies (GWAS).
Examination of ITPKC signaling pathway in KD susceptibility.

Main Results:

Identification of novel ITPKC signaling pathway involvement in KD susceptibility.
GWAS revealed functionally related susceptibility loci in Caucasian populations.
Significant progress in understanding KD genetics through identification of linked genomic regions.

Conclusions:

Genetic polymorphisms play a crucial role in Kawasaki disease pathogenesis.
Understanding genetic variants offers insights into KD's molecular mechanisms and clinical course.
Continued genetic research is vital for unraveling KD etiology and improving patient outcomes.